Tongxinluo Capsule for Diabetic Kidney Disease:A Systematic Review

Objective To assess the efficacy of Tongxinluo for diabetic kidney disease.Methods we conducted a systematic review of randomized controlled trials (RCTs) in which Tongxinluo was used to treat diabetic kidney disease.And we screened relevant studies according to predefined inclusion and exclusion criteria,evaluated the quality of the included studies,and performed meta-analyses by using The Cochrane Collaboration's Revman 5.0 software.Results A total of 11 RCTs were enrolled in the review.The results of meta-analysis showed that Tongxinluo was better on attenuating 24 hour urinary protein,BUN and UAER;Tongxinluo was not superior to no treatment on the improvement of Scr and Ccr;Tongxinluo was better than no treatment on the Regulation of blood lipids,such as TC,TG,LDL-C.However,Tongxinluo might have similar effects on the improvement of HDL-C;Tongxinluo was better than no treatment on the improvement of FBG,but xuezhikang was not superior to no treatment on the improvement of P2BG and HbA1c.Tongxinluo was better than no treatment in decreasing plasma endothelin (ET).No significant adverse effects or Allergic reactions were reported.Conclusion The evidence currently available shows that Tongxinluo has some effect and is relatively safe in treating patients with diabetic kidney disease.Due to a high risk of selection bias and detection bias in the included studies,the evidence is insufficient to determine the effect of Tongxinluo.Further large-scale trials are required to define the role of xuezhikang in the treatment of DKD.